Bacterial proteins and macromolecules

Bacterial proteins and macromolecules represent the diverse array of essential prokaryotic components that serve as the primary targets for antimicrobial therapy. This broad category includes structural elements like the peptidoglycan cell wall, the protein synthesis machinery of the 30S and 50S ribosomal subunits, and enzymes critical for genetic processes such as DNA gyrase and RNA polymerase (StatPearls, 2023). Antibiotics achieve selective toxicity by exploiting the unique biochemical properties of these bacterial targets, which are either absent or significantly different in human cells (PubMed, 2021). For instance, beta-lactams inhibit cell wall assembly by binding to penicillin-binding proteins, while fluoroquinolones interfere with DNA replication by targeting topoisomerases (NIH, 2022). However, the clinical utility of targeting these macromolecules is increasingly compromised by the global emergence of antimicrobial resistance, where bacteria develop mechanisms to modify target sites or enzymatically inactivate drugs (WHO, 2023). Understanding the interactions between drugs and these bacterial components is vital for the development of next-generation antibiotics to treat multi-drug resistant infections.

Other names

Bacterial targetsProkaryotic macromoleculesBacterial cell components

Inhibition of cell wall synthesis, inhibition of protein synthesis via 30S or 50S ribosomal subunits, inhibition of nucleic acid synthesis (DNA/RNA), and disruption of cell membrane integrity (StatPearls, 2023; PubMed, 2021).